TherapeuticsMD, Inc.
TXMD
$2.08
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -18.92% | 13.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.92% | 13.90% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -18.92% | 13.90% | |||
| SG&A Expenses | -52.63% | 79.37% | |||
| Depreciation & Amortization | -3.09% | 1.04% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -50.05% | 72.41% | |||
| Operating Income | 78.74% | -227.36% | |||
| Income Before Tax | 117.76% | -1,260.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 116.83% | -1,324.00% | |||
| Earnings from Discontinued Operations | -14.29% | -106.86% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 115.35% | -507.24% | |||
| EBIT | 78.74% | -227.36% | |||
| EBITDA | 87.16% | -336.00% | |||
| EPS Basic | 115.33% | -508.40% | |||
| Normalized Basic EPS | 119.79% | -743.18% | |||
| EPS Diluted | 114.39% | -670.00% | |||
| Normalized Diluted EPS | 119.43% | -743.18% | |||
| Average Basic Shares Outstanding | -0.01% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.56% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||